Skip to main content

OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars

Written by Customer Service on . Posted in Public Companies.

Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to to-date
Phase 2a trial follows the successful completion of OliX’s Phase 1 trial in the U.K. in November 2019OliX retains global rights to develop and commercialize OLX10010 outside AsiaSUWON, Republic of Korea, Oct. 30, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate the efficacy of OLX10010 as an adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery.“We are pleased to receive FDA clearance to advance investigation of OLX10010 and look forward to working with investigators to begin enrolling patients in the trial,” said Dong Ki Lee, Ph.D., founder and Chief Executive Officer. “Treating and reducing hypertrophic scars following surgery remains a high unmet medical need and we are excited to continue our efforts to develop this pioneering therapy and bring it to patients in the U.S.”Hypertrophic scarring occurs in 40% to 70% of patients following surgery and results from an overgrowth of collagen in the dermis (the layer of skin beneath the surface layer) that may cause functional impairment and cosmetic disfigurement.The Phase 2a study is a prospective, randomized, double-blind, intra-subject, placebo-controlled study that will assess recurrence of hypertrophic scars at 24 weeks following scar revision surgery as measured by a patient and observer scar assessment (POSAS). The trial will enroll up to 20 patients across five sites in the U.S.Asymmetric small interfering RNAAsymmetric small interfering RNA (asiRNA) is the next generation of RNAi therapeutics that offers efficient gene regulation. In comparison to existing siRNA therapeutics, OliX Pharmaceuticals’ asiRNA shows comparable gene silencing and significantly reduce siRNA-mediated side effects such as off-target gene silencing and immune stimulation.About OliX PharmaceuticalsOliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.To learn more about the company, visit https://www.olixpharma.com/eng/
To learn more about RNAi technology, visit https://www.olixpharma.com/eng/rnd/rnd01.phpMedia Contact:Jon Yu
Westwicke/ICR PR
Phone: +1.646.677.1855
jon.yu@westwicke.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.